AccuVein is a technology company.
AccuVein is a technology company.
AccuVein has raised $23.0M across 1 funding round.
AccuVein has raised $23.0M in total across 1 funding round.
AccuVein is a medical technology company specializing in vein visualization devices that use near-infrared (NIR) light to display superficial veins, valves, and bifurcations, aiding clinicians in IV insertions and vascular access procedures.[1][2][3] It serves healthcare professionals in acute care, non-acute care, and aesthetics, solving the problem of difficult vein access—which affects over 90% of hospital patients undergoing IV therapy—by improving first-attempt success rates to 92%, reducing procedure time by 78%, cutting escalation calls by 45%, and decreasing patient pain by 39%.[2][6] The flagship AV500 and AV400 devices are handheld, lightweight (10 ounces), and support hands-free use, driving growth through clinical endorsements, GSA federal contracts, and global leadership in the category.[3][5]
Founded in January 2006 and federally registered in April 2009, AccuVein is headquartered in Medford, NY, as a Delaware-incorporated for-profit manufacturer with under 500 employees, focusing on electromedical apparatus (NAICS 334510).[3] While specific founders are not detailed in available sources, the company emerged to address vascular access challenges in IV therapy, developing its pioneering Class 1 laser-based NIR device with patented True Center™ technology for permanent alignment without calibration.[1][3][6] Early traction came from its unique real-time visualization capabilities, leading to GSA contracts (most recent award July 30, 2025) and recognition as the global leader in vein visualization.[3][5]
AccuVein rides the trend of precision medtech and healthcare equity, where NIR vein visualization is recommended by leading societies to enhance decision-making amid rising demands for efficient, patient-centered care.[1][2] Timing aligns with post-pandemic focus on reducing IV complications, nurse burnout, and costs—over 90% of inpatients need IVs—while addressing disparities in vein access for diverse skin tones.[2][6] Market forces like labor shortages and value-based care favor its efficiency gains, positioning it to influence standards in vascular access, much like how imaging tech transformed other diagnostics.[1][3]
AccuVein is poised for expansion with recent federal awards and AV500 enhancements, likely penetrating more aesthetics and global markets amid aging populations and IV therapy growth.[3][6] Trends like AI integration in medtech and equity mandates will shape its path, potentially evolving influence through partnerships or next-gen portability. As the essential first step in vascular care, it ties back to transforming uncertain "sticks" into confident, equitable outcomes.[2][7]
AccuVein has raised $23.0M in total across 1 funding round.
AccuVein has raised $23.0M across 1 funding round. Most recently, it raised $23.0M Series B in July 2011.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2011 | $23.0M Series B |